lorazepam has been researched along with Panic Disorder in 16 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 7.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Panic attacks were defined using the panic symptom scale (PSS)." | 6.76 | One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. ( Demazières, A; Erb, G; Hode, Y; Luthringer, R; Mathis, A; Namer, IJ; Schunck, T, 2011) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 3.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "In the treatment of panic disorder double-blind controlled studies have demonstrated that imipramine (IMI) was effective at doses higher than 125 mg/day." | 3.69 | The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. ( Ampollini, P; Maggini, C; Marchesi, C; Signifredi, R, 1997) |
| "Panic attacks were defined using the panic symptom scale (PSS)." | 2.76 | One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. ( Demazières, A; Erb, G; Hode, Y; Luthringer, R; Mathis, A; Namer, IJ; Schunck, T, 2011) |
| "Clonazepam has several advantages over other benzodiazepines and can be considered a first-line agent for panic disorder." | 2.40 | Use of benzodiazepines in panic disorder. ( Davidson, JR, 1997) |
| "Three patients had exceptionally high seizure threshold, as determined by an empirical titration procedure." | 1.29 | Exceptionally high seizure threshold: ECT device limitations. ( Devanand, DP; Lisanby, SH; Mullen, L; Nobler, MS; Prudic, J; Sackeim, HA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Uvais, NA | 1 |
| Schunck, T | 1 |
| Mathis, A | 1 |
| Erb, G | 1 |
| Namer, IJ | 1 |
| Hode, Y | 1 |
| Demazières, A | 1 |
| Luthringer, R | 2 |
| Watanabe, T | 1 |
| Ueda, M | 1 |
| Saeki, Y | 1 |
| Hirokane, G | 1 |
| Morita, S | 1 |
| Okawa, M | 1 |
| Akiyama, K | 1 |
| Shimoda, K | 1 |
| Gilles, C | 1 |
| Marchesi, C | 2 |
| De Panfilis, C | 1 |
| Cantoni, A | 1 |
| Giannelli, MR | 1 |
| Maggini, C | 2 |
| Clivaz, E | 1 |
| Chauvet, I | 1 |
| Zullino, D | 1 |
| Niquille, M | 1 |
| Maris, S | 1 |
| Cicotti, A | 1 |
| Lazignac, C | 1 |
| Lazignac Coralie, C | 1 |
| Damsa, C | 1 |
| Chung, CK | 1 |
| Remington, ND | 1 |
| Suh, BY | 1 |
| Robinson, D | 1 |
| Casso, DE | 1 |
| Omar, SJ | 1 |
| Tinklenberg, JR | 1 |
| Cohen, SI | 1 |
| Tiffon, L | 1 |
| Coplan, JD | 1 |
| Papp, LA | 1 |
| Gorman, JM | 1 |
| Lisanby, SH | 1 |
| Devanand, DP | 1 |
| Nobler, MS | 1 |
| Prudic, J | 1 |
| Mullen, L | 1 |
| Sackeim, HA | 1 |
| Davidson, JR | 1 |
| Ampollini, P | 1 |
| Signifredi, R | 1 |
| Maltsberger, JT | 1 |
| Tsen, LC | 1 |
| Datta, S | 1 |
| Kopp, M | 1 |
| Holzner, B | 1 |
| Brugger, A | 1 |
| Nachbaur, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Bupropion on Seizure Threshold in Depressed Patients[NCT03126682] | Phase 4 | 10 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Scoring of depressive symptoms on the Montgomery Asberg Depression Rating Scale, maximum 60 , minimum 0. Higher scores mean worse outcome. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Scored on day 1 and day 2 after ECT session
| Intervention | Scored on a scale (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 2.60 |
| Wellbutrin During ECT 2 | 3.60 |
Duration of seizures with ECT. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Measured at day 1 and day 2
| Intervention | seconds (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 26.2 |
| Wellbutrin During ECT 2 | 29.6 |
Charge in Millicoulombs at which subject gets a seizure with ECT. First measurement on day 1 of electroconvulsive treatment (ECT) and second measurement on day 2 of electroconvulsive therapy (ECT), separated by 1 day interval. This outcome measure was not measured at baseline. (NCT03126682)
Timeframe: Measured at day 1 and day 2
| Intervention | millicoulombs (Mean) |
|---|---|
| Wellbutrin During ECT 1 | 23.04 |
| Wellbutrin During ECT 2 | 19.68 |
2 reviews available for lorazepam and Panic Disorder
| Article | Year |
|---|---|
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.
Topics: Apomorphine; Cognition Disorders; Dopamine Agonists; Excitatory Amino Acid Antagonists; GABA Modulat | 2007 |
Use of benzodiazepines in panic disorder.
Topics: Alprazolam; Benzodiazepines; Clonazepam; Humans; Lorazepam; Panic Disorder; Treatment Outcome | 1997 |
3 trials available for lorazepam and Panic Disorder
| Article | Year |
|---|---|
One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Attention; Cerebral Cortex; Cross-Over Studi | 2011 |
High plasma concentrations of paroxetine impede clinical response in patients with panic disorder.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Asian People; Azepines; Diagnostic and Statis | 2007 |
Effect of pharmacological treatment on temperament and character in panic disorder.
Topics: Adult; Anxiety; Character; Citalopram; Female; Follow-Up Studies; GABA Modulators; Humans; Lorazepam | 2008 |
11 other studies available for lorazepam and Panic Disorder
| Article | Year |
|---|---|
Psychological Impact of the COVID-19 Pandemic Among the Elderly: A Case Series From India.
Topics: Acetamides; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Betacoronavirus; Ci | 2020 |
Topiramate and panic attacks in patients with borderline personality disorder.
Topics: Adolescent; Anti-Anxiety Agents; Borderline Personality Disorder; Emergency Medical Services; Female | 2008 |
Estrogen replacement therapy may reduce panic symptoms.
Topics: Adult; Amitriptyline; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens, | 1995 |
Possible oral lactate exacerbation of panic disorder.
Topics: Administration, Oral; Adult; Drug Synergism; Female; Humans; Lactates; Lactic Acid; Lorazepam; Panic | 1995 |
Alcohol and benzodiazepines generate anxiety, panic and phobias.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; Female; | 1995 |
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Desipramine; Drug Therapy, Combination; Female; | 1994 |
Exceptionally high seizure threshold: ECT device limitations.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Bipolar Disorder; Depressive Disorder; Electroconvulsi | 1996 |
The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
Topics: Agoraphobia; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Arousal; Dose-Response Relations | 1997 |
Robert Salter: attempted suicide by jumping from a high bridge.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Denial, Psychological; Diagnosis, Dif | 1998 |
Panic attacks and lactated Ringer's solution: is there a relationship?
Topics: Adult; Analgesia, Epidural; Anesthetics, Local; Diagnostic Errors; Female; Humans; Isotonic Solution | 1999 |
Successful management of claustrophobia and depression during allogeneic SCT.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Cognitive Behavioral Therapy; Combined Modality Therapy; Cranio | 2001 |